Antibody composition for detecting minimal residual lesions of multiple myeloma, kit and application

A multiple myeloma and antibody composition technology, which is applied in the field of hematological tumor treatment efficacy monitoring, can solve the problems of inability to accurately circle plasma cells, premature termination of treatment, and no unified recommendation for flow cytometry antibody combination schemes, etc.

Inactive Publication Date: 2020-11-10
BEIJING JISHUITAN HOSPITAL
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the application of the recently marketed new antibody drug CD38 monoclonal antibody (DARA for short) targeting myeloma cells has brought difficulties to MRD monitoring, because after DARA treatment, the expression of CD38 antigen on the surface of bone marrow plasma cells in patients will be down-regulated or even converted to MRD. Negative (reports in the literature and previous studies of our research group have confirmed this phenomenon), at this time the currently recommended antibody combination

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody composition for detecting minimal residual lesions of multiple myeloma, kit and application
  • Antibody composition for detecting minimal residual lesions of multiple myeloma, kit and application
  • Antibody composition for detecting minimal residual lesions of multiple myeloma, kit and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0018] In order to enable those skilled in the art to better understand the solutions of the present invention, the following will clearly and completely describe the technical solutions in the embodiments of the present invention in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only It is an embodiment of a part of the present invention, but not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by persons of ordinary skill in the art without making creative efforts shall fall within the protection scope of the present invention.

[0019] It should be noted that the terms "first" and "second" in the description and claims of the present invention and the above drawings are used to distinguish similar objects, but not necessarily used to describe a specific sequence or sequence. It is to be understood that the data so used are interchangeable under appropriate ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an antibody composition for detecting multiple myeloma minimal residual diseases, a kit and application, and belongs to the technical field of blood tumor treatment effect monitoring. According to the novel flow antibody combination scheme capable of being used for MRD monitoring of myeloma patients disclosed by the invention, CD319 or CD269 and other seven antibodies (CD138/CD38/CD184/CD27/CD19/CD56/ckappa/clamda) are combined to form a fixed combination of two groups of antibodies; through verification of 303 cases of myeloma patients, the antibody combination is feasible, accurate, convenient and fast, can be used for MRD monitoring after conventional chemotherapeutic drug treatment, and provides a good solution for the problem that MRD monitoring is difficult after DARA treatment.

Description

technical field [0001] The invention belongs to the technical field of curative effect monitoring for hematological tumor treatment, and relates to a flow-type antibody combination scheme, in particular to an antibody composition, kit and application for detecting multiple myeloma minimal residual disease. Background technique [0002] Multiple myeloma is a hematologic malignancy that remains incurable despite the advent of novel targeted drugs that have greatly improved patient survival. The consensus of the current industry guidelines recommends that patients receive continuous treatment, and the endpoint of treatment depends on whether minimal residual disease (MRD) is negative. At present, the main means of monitoring MRD is the immunophenotyping technology of flow cytometry. By analyzing the bone marrow samples of patients, it is determined whether they are MRD-, especially for patients whose MRD- status lasts for more than 1 year after hematopoietic stem cell transplan...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/577G01N33/574G01N33/68
CPCG01N33/57407G01N33/57484G01N33/577G01N33/6872G01N2800/52
Inventor 鲍立褚彬陆敏秋石磊高珊王宇彤
Owner BEIJING JISHUITAN HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap